NEW YORK (GenomeWeb) – Vela Diagnostics said today that it has completed the listing of its next-generation sequencing system with the US Food and Drug Administration as a class II medical device.

The diagnostic system includes the Sentosa ST401 instrument for automated template preparation and enrichment, the Sentosa SQ301 sequencer and server, and the Sentosa SQ Reporter for data analysis and report generation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.